24-09-2022  (347 lectures) Categoria: Streptomycin

Streptomycin - Estreptomicina

Jump to navigationJump to search

Clinical data
AHFS/Drugs.com Monograph
License data
Routes of
Intramuscular, intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 84% to 88% IM (est.)[1] 0% by mouth
Elimination half-life 5 to 6 hours
Excretion Kidney
CAS Number
PubChem CID
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard 100.000.323 Edit this at Wikidata
Chemical and physical data
Formula C21H39N7O12
Molar mass 581.580 g¬∑mol‚ąí1
3D model (JSmol)
Melting point 12¬†¬įC (54¬†¬įF)
‚ėícheck (what is this?) (verify)

Streptomycin is an antibiotic medication used to treat a number of bacterial infections,[3] including tuberculosis, Mycobacterium avium complex, endocarditis, brucellosis, Burkholderia infection, plague, tularemia, and rat bite fever.[3] For active tuberculosis it is often given together with isoniazid, rifampicin, and pyrazinamide.[4] It is administered by injection into a vein or muscle.[3]

Common side effects include vertigo, vomiting, numbness of the face, fever, and rash.[3] Use during pregnancy may result in permanent deafness in the developing baby.[3] Use appears to be safe while breastfeeding.[4] It is not recommended in people with myasthenia gravis or other neuromuscular disorders.[4] Streptomycin is an aminoglycoside.[3] It works by blocking the ability of 30S ribosomal subunits to make proteins, which results in bacterial death.[3]

Albert Schatz first isolated streptomycin in 1943 from Streptomyces griseus.[5][6] It is on the World Health Organization's List of Essential Medicines.[7] The World Health Organization classifies it as critically important for human medicine.[8]




Streptomycin is traditionally given intramuscularly, and in many nations is only licensed to be administered intramuscularly, though in some regions the drug may also be administered intravenously.[1]


Streptomycin also is used as a pesticide, to combat the growth of bacteria beyond human applications. Streptomycin controls bacterial diseases of certain fruit, vegetables, seed, and ornamental crops. A major use is in the control of fireblight on apple and pear trees. As in medical applications, extensive use can be associated with the development of resistant strains. Streptomycin could potentially be used to control cyanobacterial blooms in ornamental ponds and aquaria.[10] While some antibacterial antibiotics are inhibitory to certain eukaryotes, this seems not to be the case for streptomycin, especially in the case of anti-fungal activity.[11]

Cell culture

Streptomycin, in combination with penicillin, is used in a standard antibiotic cocktail to prevent bacterial infection in cell culture.[medical citation needed]

Protein purification

When purifying protein from a biological extract, streptomycin sulfate is sometimes added as a means of removing nucleic acids. Since it binds to ribosomes and precipitates out of solution, it serves as a method for removing rRNA, mRNA, and even DNA if the extract is from a prokaryote.[medical citation needed]

Side effects

The most concerning side effects, as with other aminoglycosides, are kidney toxicity and ear toxicity.[12] Transient or permanent deafness may result. The vestibular portion of cranial nerve VIII (the vestibulocochlear nerve) can be affected, resulting in tinnitus, vertigo, ataxia, kidney toxicity, and can potentially interfere with diagnosis of kidney malfunction.[13]

Common side effects include vertigo, vomiting, numbness of the face, fever, and rash. Fever and rashes may result from persistent use.[citation needed]

Use is not recommended during pregnancy.[3] Congenital deafness has been reported in children whose mothers received streptomycin during pregnancy.[3] Use appears to be okay while breastfeeding.[4]

It is not recommended in people with myasthenia gravis.[4]

Mechanism of action

Streptomycin has two mechanism of action depending on what conformation (isomer) is at in the system in which it will work. Isomer A functions as a protein synthesis inhibitor. It binds to the small 16S rRNA of the 30S subunit of the bacterial ribosome irreversibly, interfering with the binding of formyl-methionyl-tRNA to the 30S subunit.[14] This leads to codon misreading, eventual inhibition of protein synthesis and ultimately death of microbial cells through mechanisms that are still not understood. Speculation on this mechanism indicates that the binding of the molecule to the 30S subunit interferes with 30S subunit association with the mRNA strand. This results in an unstable ribosomal-mRNA complex, leading to a frameshift mutation and premature stopping of protein synthesis; leading to cell death.[15] As human and bacterial both have ribosomes, streptomycin has significant side effects in human cells. At low concentrations, however, streptomycin only inhibits growth of the bacteria by inducing prokaryotic ribosomes to misread mRNA.[16]

Streptomycin isomer B is a peptidoglycan synthesis inhibitor much like lysozyme. It binds to the glycosidic linkages and breaks them through a SN2 mechanism.[citation needed] This leads to bacterial cell walls' integrity being compromised, ultimately resulting in death of microbial cells.[citation needed]

Streptomycin is an antibiotic that inhibits both Gram-positive and Gram-negative bacteria,[17] and is therefore a useful broad-spectrum antibiotic.


Streptomycin was first isolated on October 19, 1943, by Albert Schatz, a PhD student in the laboratory of Selman Abraham Waksman at Rutgers University in a research project funded by Merck and Co.[18][19] Waksman and his laboratory staff discovered several antibiotics, including actinomycin, clavacin, streptothricin, streptomycin, grisein, neomycin, fradicin, candicidin, and candidin. Of these, streptomycin and neomycin found extensive application in the treatment of numerous infectious diseases. Streptomycin was the first antibiotic cure for tuberculosis (TB). In 1952 Waksman was the recipient of the Nobel Prize in Physiology or Medicine in recognition "for his discovery of streptomycin, the first antibiotic active against tuberculosis".[20] Waksman was later accused of playing down the role of Schatz who did the work under his supervision, claiming that Elizabeth Bugie had a more important role in its development.[21][22][23][24][25] Schatz sued both Dr. Waksman and the Rutgers Research and Endowment Foundation, wanting to be given credited as co-discover and receive the royalties for the streptomycin.[26] By the end of the settlement, Waksman would receive a 10% royalty, while Schatz got 3% and compensation for his missed royalties.[27] The rest of the lab shared the remaining 7% of the royalties, in which Bugie received 0.2%.[citation needed]

Bugie was pursuing a master's degree in Waksman's lab at Rutgers University at this time. Prior to this, she received her bachelor's degree in microbiology at New Jersey College for Women.[26] Although Bugie was considered to be the second author on the Proceedings of the Society for Experimental Biology paper, she was not listed on the patent submission.[26] Bugie's contributions to Wakeman's lab were great. In addition to her work on streptomycin, she also helped develop other antimicrobial substances,[28] had two peer-reviewed publications,[29][30] and researched the use of antimicrobals against plant pathogens,[31] among several other important contributions to the scientific field, particularly in regard to microbiology.

A scientist at Rutger's University making a streptomycin assay.

The Rutgers team reported streptomycin in the medical literature in January 1944.[32] Within months they began working with¬†William Feldman and¬†H. Corwin Hinshaw of the¬†Mayo Clinic with hopes of starting a human clinical trial of streptomycin in tuberculosis.[33]:‚Ää209‚Äď241 The difficulty at first was even producing enough streptomycin to do a trial, because the research laboratory methods of creating small batches had not yet been¬†translated to commercial large-batch production. They managed to do an animal study in a few guinea pigs with just 10 grams of the scarce drug, demonstrating survival.[33]:‚Ää209‚Äď241 This was just enough evidence to get Merck & Co. to divert some resources from the young penicillin production program to start work toward streptomycin production.[33]:‚Ää209‚Äď241

At the end of World War II, the United States Army experimented with streptomycin to treat life-threatening infections at a military hospital in¬†Battle Creek, Michigan. The first person who was treated with streptomycin did not survive; the second person survived but became blind as a side effect of the treatment. In March 1946, the third person‚ÄĒRobert J. Dole, later Majority Leader of the United States Senate and presidential nominee‚ÄĒexperienced a rapid and robust recovery.[34]

The first randomized trial of streptomycin against pulmonary tuberculosis was carried out in 1946 through 1948 by the¬†MRC Tuberculosis Research Unit under the chairmanship of Geoffrey Marshall (1887‚Äď1982). The trial was neither¬†double-blind nor¬†placebo-controlled.[35] It is widely accepted to have been the first randomized curative trial.[36]

Results showed efficacy against TB, albeit with minor toxicity and acquired bacterial resistance to the drug.[35]

New Jersey

Because streptomycin was isolated from a microbe discovered on New Jersey soil, and because of its activity against tuberculosis and Gram negative organisms, and in recognition of both the microbe and the antibiotic in the history of New Jersey, S. griseus was nominated as the Official New Jersey state microbe. The draft legislation was submitted by Senator Sam Thompson (R-12) in May 2017 as bill S3190 and Assemblywoman Annette Quijano (D-20) in June 2017 as bill A31900. The bill was passed on 2018-01-08 The bill designates Streptomyces griseus as New Jersey State Microbe (New Jersey Senate Bill 3190 (2017). Passed in January 2018.[citation needed]

See also

  • Philip D'Arcy Hart ‚Äď The British medical researcher and pioneer in tuberculosis treatment in the early twentieth century.


  1. ^¬†Jump up to:a b Zhu M, Burman WJ, Jaresko GS, Berning SE, Jelliffe RW, Peloquin CA (October 2001).¬†"Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis".¬†Pharmacotherapy.¬†21 (9): 1037‚Äď1045.¬†doi:10.1592/phco.21.13.1037.34625.¬†PMID 11560193.¬†S2CID 24111273.¬†Archived from the original on October 5, 2011. Retrieved¬†May 25, 2010.
  2. ^ "Streptomycin Use During Pregnancy". Drugs.com. October 24, 2019. Retrieved February 11, 2020.
  3. ^ Jump up to:a b c d e f g h i "Streptomycin Sulfate". The American Society of Health-System Pharmacists. Archived from the original on December 20, 2016. Retrieved December 8, 2016.
  4. ^ Jump up to:a b c d e f World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 136, 144, 609. hdl:10665/44053. ISBN 9789241547659.
  5. ^ Torok E, Moran E, Cooke F (2009). Oxford Handbook of Infectious Diseases and Microbiology. OUP Oxford. p. Chapter 2. ISBN 9780191039621. Archived from the original on September 8, 2017.
  6. ^ Renneberg R, Demain AL (2008). Biotechnology for Beginners. Elsevier. p. 103. ISBN 9780123735812. Archived from the original on September 10, 2017.
  7. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  8. ^ World Health Organization (2019). Critically important antimicrobials for human medicine (6th revision ed.). Geneva: World Health Organization. hdl:10665/312266. ISBN 9789241515528. License: CC BY-NC-SA 3.0 IGO.
  9. ^ "Clinicians Tularemia". www.cdc.gov. September 2016. Retrieved November 8, 2017.
  10. ^ Qian H, Li J, Pan X, Sun Z, Ye C, Jin G, Fu Z (March 2012). "Effects of streptomycin on growth of algae Chlorella vulgaris and Microcystis aeruginosa".¬†Environ. Toxicol.¬†27 (4): 229‚Äď37.¬†Bibcode:2012EnTox..27..229Q.¬†doi:10.1002/tox.20636.¬†PMID 20725941.¬†S2CID 2380252.
  11. ^ Reilly HC, Schatz A, Waksman SA (June 1945).¬†"Antifungal Properties of Antibiotic Substances".¬†J. Bacteriol.¬†49 (6): 585‚Äď94.¬†doi:10.1128/jb.49.6.585-594.1945.¬†PMC 374091.¬†PMID 16560957.
  12. ^ Prayle A, Watson A, Fortnum H, Smyth A (July 2010).¬†"Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis".¬†Thorax.¬†65 (7): 654‚Äď8.¬†doi:10.1136/thx.2009.131532.¬†PMC 2921289.¬†PMID 20627927.
  13. ^ Syal K, Srinivasan A, Banerjee D (2013). "Streptomycin interference in Jaffe reaction ‚ÄĒ Possible false positive creatinine estimation in excessive dose exposure".¬†Clinical Biochemistry.¬†46 (1‚Äď2): 177‚Äď179.¬†doi:10.1016/j.clinbiochem.2012.10.031.¬†PMID 23123914.
  14. ^ Sharma D, Cukras AR, Rogers EJ, Southworth DR, Green R (December 7, 2007).¬†"Mutational analysis of S12 protein and implications for the accuracy of decoding by the ribosome".¬†Journal of Molecular Biology.¬†374 (4): 1065‚Äď76.¬†doi:10.1016/j.jmb.2007.10.003.¬†PMC 2200631.¬†PMID 17967466.
  15. ^ Raymon LP (2011). COMLEX Level 1 Pharmacology Lecture Notes. Miami, FL: Kaplan, Inc. p. 181. CM4024K.
  16. ^ Voet, Donald & Voet, Judith G. (2004). Biochemistry (3rd ed.). John Wiley & Sons. p. 1341. ISBN 978-0-471-19350-0.
  17. ^ Jan-Thorsten Schantz; Kee-Woei Ng (2004). A manual for primary human cell culture. World Scientific. p. 89.
  18. ^ Comroe JH Jr (1978). "Pay dirt: the story of streptomycin. Part I: from Waksman to Waksman".¬†American Review of Respiratory Disease.¬†117 (4): 773‚Äď781.¬†doi:10.1164/arrd.1978.117.4.773 (inactive July 31, 2022).¬†PMID 417651.
  19. ^ Kingston W (July 2004). "Streptomycin, Schatz v. Waksman, and the balance of credit for discovery".¬†J Hist Med Allied Sci.¬†59 (3): 441‚Äď62.¬†doi:10.1093/jhmas/jrh091.¬†PMID 15270337.¬†S2CID 27465970.
  20. ^ Official list of Nobel Prize Laureates in Medicine Archived June 9, 2017, at the Wayback Machine
  21. ^ "Obiturary: Elizabeth Gregory / Did McCandless woman get fair shake for role in discovery of streptomycin?". old.post-gazette.com. Retrieved November 7, 2021.
  22. ^ Wainwright, M. (1990). Miracle Cure: The Story of Penicillin and the Golden Age of Antibiotics. Blackwell. ISBN 9780631164920. Archived from the original on September 10, 2017. Retrieved December 29, 2014.
  23. ^ Wainwright M (1991). "Streptomycin: discovery and resultant controversy".¬†Hist Philos Life Sci.¬†13 (1): 97‚Äď124.¬†PMID 1882032.
  24. ^ Kingston W (July 1, 2004). "Streptomycin, Schatz v. Waksman, and the balance of credit for discovery".¬†Journal of the History of Medicine and Allied Sciences.¬†59 (3): 441‚Äď462.¬†doi:10.1093/jhmas/jrh091.¬†ISSN 0022-5045.¬†PMID 15270337.¬†S2CID 27465970.
  25. ^ Pringle P (2012). Experiment Eleven: Dark Secrets Behind the Discovery of a Wonder Drug. New York: Walker & Company. ISBN 978-1620401989.
  26. ^¬†Jump up to:a b c "Elizabeth Bugie ‚Äď the invisible woman in the discovery of streptomycin".¬†The Scientista Foundation. Retrieved¬†November 30, 2021.
  27. ^ "The Forgotten Women of the Antibiotics Race". Lady Science. Retrieved December 21, 2021.
  28. ^ Whitaker RJ, Barton HB, eds. (2018). "Women Microbiologists at Rutgers in the Early Golden Age of Antibiotics". Women in Microbiology. American Society of Microbiology. doi:10.1128/9781555819545. ISBN 9781555819545.
  29. ^ Waksman SA, Bugie E (September 1943).¬†"Strain Specificity and Production of Antibiotic Substances: II. Aspergillus Flavus-Oryzae Group".¬†Proceedings of the National Academy of Sciences of the United States of America.¬†29 (9): 282‚Äď288.¬†Bibcode:1943PNAS...29..282W.¬†doi:10.1073/pnas.29.9.282.¬†PMC 1078613.¬†PMID 16578091.
  30. ^ Waksman SA, Bugie E (November 1944).¬†"Chaetomin, a New Antibiotic Substance Produced by Chaetomium cochliodes: I. Formation and Properties".¬†Journal of Bacteriology.¬†48 (5): 527‚Äď530.¬†doi:10.1128/jb.48.5.527-530.1944.¬†PMC 374002.¬†PMID 16560863.
  31. ^ Waksman SA, Bugie E (October 1, 1943). "Action of Antibiotic Substances Upon Ceratostotnella ulmi".¬†Experimental Biology and Medicine.¬†54 (1): 79‚Äď82.¬†doi:10.3181/00379727-54-14310.¬†ISSN 1535-3702.¬†S2CID 87534513.
  32. ^ Schatz A, Bugle E, Waksman SA (1944). "Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria".¬†Experimental Biology and Medicine.¬†55: 66‚Äď69.¬†doi:10.3181/00379727-55-14461.¬†S2CID 33680180.
  33. ^¬†Jump up to:a b c Ryan F (1993).¬†The forgotten plague: how the battle against tuberculosis was won‚ÄĒand lost. Boston: Little, Brown.¬†ISBN 978-0316763806.
  34. ^ Cramer RB (1992).¬†What it takes¬†: the way to the White House (1st¬†ed.). New York: Random House. pp.¬†110‚Äď111.¬†ISBN 978-0-394-56260-5.
  35. ^¬†Jump up to:a b D'Arcy Hart P (August 1999).¬†"A change in scientific approach: from alternation to randomised allocation in clinical trials in the 1940s".¬†BMJ.¬†319 (7209): 572‚Äď3.¬†doi:10.1136/bmj.319.7209.572.¬†PMC 1116443.¬†PMID 10463905.
  36. ^ Metcalfe NH (February 2011). "Sir Geoffrey Marshall (1887-1982): respiratory physician, catalyst for anaesthesia development, doctor to both Prime Minister and King, and World War I Barge Commander".¬†J Med Biogr.¬†19 (1): 10‚Äď4.¬†doi:10.1258/jmb.2010.010019.¬†PMID 21350072.¬†S2CID 39878743.

Further reading

External links

  • "Streptomycin".¬†Drug Information Portal. U.S. National Library of Medicine.

versió per imprimir

Comentaris publicats

    Afegeix-hi un comentari:

    Nom a mostrar:
    Genera una nova imatge
    Introdu√Įu el codi de seguretat
    Accepto les condicions d'ús següents:

    Per a participar en els comentaris l'usuari es compromet a complir i acceptar les següents normes bàsiques de conducta:

    • Respectar les opinions de la resta dels participants al fòrum, tot i no compartir-les necessàriament.
    • Abstenir-se d'insultar o utilitzar un llenguatge ofensiu, racista, violent o xenòfob, i no tenir cap conducta contrària a la legislació vigent i a l'ordre públic.
    • No enviar cap contingut amb copyright sense el permís del propietari. Si es considera oportú facilitar continguts d'internet amb copyright, cal escriure la URL completa perquè els altres usuaris puguin enllaçar-hi i descarregar-se els continguts des de la pàgina propietària.
    • Publicitat: No es permet enviar continguts promocionals i/o publicitaris.